Occident Group

Lymphatica Medtech SA is a Swiss company that specializes in the design and manufacture of medical devices aimed at treating lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed innovative solutions such as the LymphoDrain system, which includes an active implantable lymphatic bypass that integrates a magnetically controlled micropump and subcutaneous catheters. This technology is designed to re-establish lymphatic circulation by internally draining lymphatic fluid from multiple points in the affected limb, providing a minimally invasive remedy for patients suffering from lymphedema. Lymphatica Medtech's commitment to advancing treatment options in this field reflects its focus on improving patient outcomes through cutting-edge medical technology.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform that utilizes magnetic blood purification technology to address infections and other health ailments. Hemotune's innovative approach involves the use of magnetic beads, which facilitate the selective and efficient removal of large biomolecules from the bloodstream. This technology focuses on the immunological aspects of conditions like sepsis, allowing for targeted treatment that addresses multiple disease pathways. By enhancing the purification of blood in acute care settings, Hemotune aims to improve patient outcomes for those suffering from blood-related diseases.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.

Altavo is a medical device company that leverages machine learning and advanced sensor technology to enhance the lives of individuals who have lost their voice. It specializes in creating custom, natural-sounding artificial voices for people with speech disorders, enabling them to communicate more effectively.

Chipmetrics specializes in developing metrology chips and wafers to enhance semiconductor process control. Its primary product, PillarHall test chips, enables accurate thin film conformality characterization, accelerating applications of conformal 3D thin films in advanced materials and microelectronics manufacturing.

ReCatalyst develops advanced catalysts for next-generation PEM fuel cells. It specializes in creating patented platinum-alloy nano-catalysts that enhance stability and reduce platinum usage, aiming to facilitate the decarbonization of energy and transport sectors through applications like green hydrogen production.

EBAMed develops a non-invasive ultrasound-based device to monitor and treat heart motion using proton beams. Founded in 2018, the company is based in Geneva, Switzerland.

Lunaphore develops automated tissue staining platforms for spatial biology research. Its technology uses microfluidic chips to analyze and classify tumors, enabling efficient cancer diagnostic assays.

iThera Medical develops biomedical imaging technology based on photonic molecular imaging and multispectral optoacoustic tomography (MSOT) for preclinical and clinical applications. The company leverages the photoacoustic effect to visualize and quantify anatomical, functional, and molecular information in vivo, including deep tissue visualization and real-time imaging, enabling non-invasive assessment of tumors and inflammatory diseases. Founded in 2010 as a spin-off from Helmholtz Zentrum München, iThera Medical focuses on advancing MSOT technology for use in preclinical research and clinical trials, supporting researchers and clinicians in obtaining deeper insights into biological processes without invasive procedures.

Founded in 2018, Resistell develops and markets a diagnostic device for phenotypic antibiotic susceptibility testing. Its unique method detects movement caused by living bacterial cells to determine bacterial resistance to antibiotics.

core sensing breathes new life into machines. The innovative coreIN product line integrates innovative IoT sensor technology into standard mechanical components. This patented technology enables easy implementation and real-time data collection - without complex redesigns. Smart components, smart insights coreIN goes far beyond simple component replacement. The smart components provide valuable real-time data and intelligent analytics that optimize functionality. The robust IoT sensor platform coreNET ensures a seamless connection from the sensor to the cloud. This enables breakthrough products and services with high added value. The patented coreIN technology measures loads directly at the source of potential failures, enabling comprehensive machine insight. Smart sensors with advanced algorithms and AI capabilities accurately analyze machine condition and performance. Successful partnerships for breakthrough innovation Together with our partners, we develop intelligent series products that set new standards. Our customers include well-known companies in various industries, including Roll Forming Machines, Conveyor Belts & Trucks.

Avelo focuses on saving lives through swift and precise infectious disease diagnoses in primary care settings. It specializes in manufacturing breath aerosol diagnostic equipment designed to enhance tuberculosis diagnosis via a non-invasive, painless breath collection device. This enables faster, accurate diagnoses using existing PCR testing infrastructure, facilitating earlier appropriate treatment and rapid patient referral.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

Code Intelligence GmbH, founded in 2017 and based in Bonn, Germany, specializes in developing advanced security software for application developers. The company offers an automated application security testing platform that employs coverage-based fuzzing and symbolic code execution to help identify and rectify security vulnerabilities in code. By automating various software attack simulations, Code Intelligence enables organizations to implement continuous security testing, significantly reducing the level of expert knowledge required for setup. Their solutions are designed to enhance the reliability and security of software, serving a diverse clientele that includes major global corporations such as Bosch, Deutsche Börse Group, and Deutsche Telekom.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform that utilizes magnetic blood purification technology to address infections and other health ailments. Hemotune's innovative approach involves the use of magnetic beads, which facilitate the selective and efficient removal of large biomolecules from the bloodstream. This technology focuses on the immunological aspects of conditions like sepsis, allowing for targeted treatment that addresses multiple disease pathways. By enhancing the purification of blood in acute care settings, Hemotune aims to improve patient outcomes for those suffering from blood-related diseases.

Lunaphore develops automated tissue staining platforms for spatial biology research. Its technology uses microfluidic chips to analyze and classify tumors, enabling efficient cancer diagnostic assays.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform that utilizes magnetic blood purification technology to address infections and other health ailments. Hemotune's innovative approach involves the use of magnetic beads, which facilitate the selective and efficient removal of large biomolecules from the bloodstream. This technology focuses on the immunological aspects of conditions like sepsis, allowing for targeted treatment that addresses multiple disease pathways. By enhancing the purification of blood in acute care settings, Hemotune aims to improve patient outcomes for those suffering from blood-related diseases.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.

Code Intelligence GmbH, founded in 2017 and based in Bonn, Germany, specializes in developing advanced security software for application developers. The company offers an automated application security testing platform that employs coverage-based fuzzing and symbolic code execution to help identify and rectify security vulnerabilities in code. By automating various software attack simulations, Code Intelligence enables organizations to implement continuous security testing, significantly reducing the level of expert knowledge required for setup. Their solutions are designed to enhance the reliability and security of software, serving a diverse clientele that includes major global corporations such as Bosch, Deutsche Börse Group, and Deutsche Telekom.

Lunaphore develops automated tissue staining platforms for spatial biology research. Its technology uses microfluidic chips to analyze and classify tumors, enabling efficient cancer diagnostic assays.

Founded in 2018, Resistell develops and markets a diagnostic device for phenotypic antibiotic susceptibility testing. Its unique method detects movement caused by living bacterial cells to determine bacterial resistance to antibiotics.

GNA Biosolutions is a molecular technology company located in Martinsried, Germany, specializing in the development of innovative molecular diagnostic devices for detecting and analyzing DNA. The company utilizes its proprietary Pulse Controlled Amplification technology to enhance nucleic acid amplification and detection, featuring rapid heating and cooling rates. This advancement allows laboratories to efficiently diagnose and amplify human pathogens and DNA, simplifying the molecular testing process. GNA Biosolutions aims to make the power of molecular testing accessible to a broader audience, facilitating both laboratory and on-site applications, as well as Point of Care solutions.

Founded in 2018, Resistell develops and markets a diagnostic device for phenotypic antibiotic susceptibility testing. Its unique method detects movement caused by living bacterial cells to determine bacterial resistance to antibiotics.

iThera Medical develops biomedical imaging technology based on photonic molecular imaging and multispectral optoacoustic tomography (MSOT) for preclinical and clinical applications. The company leverages the photoacoustic effect to visualize and quantify anatomical, functional, and molecular information in vivo, including deep tissue visualization and real-time imaging, enabling non-invasive assessment of tumors and inflammatory diseases. Founded in 2010 as a spin-off from Helmholtz Zentrum München, iThera Medical focuses on advancing MSOT technology for use in preclinical research and clinical trials, supporting researchers and clinicians in obtaining deeper insights into biological processes without invasive procedures.

Lunaphore develops automated tissue staining platforms for spatial biology research. Its technology uses microfluidic chips to analyze and classify tumors, enabling efficient cancer diagnostic assays.

Adivo GmbH is a veterinary biotechnology company based in Planegg, Germany, that focuses on developing species-specific therapeutic antibodies for companion animals, particularly dogs. The company aims to address serious diseases in pets while also exploring the potential for therapies applicable to other species. Adivo utilizes a new, fully synthetic, dog-specific drug library to isolate antibodies with optimal properties through phage display technology. The team at Adivo brings extensive experience from the development of human therapeutic antibodies, leveraging this expertise to innovate within the field of veterinary medicine. As a spin-off of MorphoSys AG, Adivo is positioned to advance therapeutic options for pets, contributing to improved health outcomes in companion animals.

InSphero specializes in the production and application of organotypic 3D cell culture models for various applications. It offers a range of assay-ready microtissues derived from liver, pancreas, tumor, heart, brain, and skin cells, along with optimized media and platforms for their generation and cultivation. The company's products include human and rat liver microtissues, pancreatic microislets, tumor microtissues, custom-made microtissues, cytotoxicity assay kits, and a human liver disease discovery platform. InSphero also provides services such as hepatotoxicity testing, oncology service packs, and embryonic stem cell test services. Its 3D InSight microtissues are used in toxicity testing, drug metabolism studies, cancer research, stem cell research, and disease modeling.

advanceCOR is a clinical drug development company focused on therapeutics and diagnostics for heart and vascular diseases. Its activities span research, development, and plans for commercialization to enable personalized treatment of cardiovascular conditions. Lead candidates include Revacept, a human Fc fusion protein that prevents local platelet activation at sites of vascular injury; COR-2, a recombinant protein that interferes with foam cell formation and the uptake of cholesterol; and COR-3, a recombinant protein that binds to atherosclerotic plaques and bi-specifically captures circulating progenitor cells to promote plaque healing. The company also develops antibodies and fusion proteins targeting platelet receptors and other components involved in arterial thrombosis and plaque progression, with an emphasis on addressing acute events such as myocardial infarction and stroke.

Founded in 2010, Implandata specializes in developing innovative medical technologies for glaucoma management. Its flagship product is Eyemate, an implantable micro sensor that continuously measures intraocular pressure, improving glaucoma patient care.

Numbrs, headquartered in Zurich, Switzerland, is a customer-focused financial services company. It offers a mobile banking platform that allows users to manage their existing bank accounts and personal finances, and purchase financial products from various providers at competitive prices. Numbrs, with over 100 employees, does not operate as a bank itself.

Lunaphore develops automated tissue staining platforms for spatial biology research. Its technology uses microfluidic chips to analyze and classify tumors, enabling efficient cancer diagnostic assays.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, Versantis aims to address significant unmet medical needs for patients globally. Its lead candidate, VS-01, is currently in preclinical development and has the potential to be the first treatment for acute liver disease while simultaneously supporting multiple failing organs. VS-01 has received Orphan Drug Designation for its application in acute liver failure. The company also has additional treatments in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent substantial market opportunities and underscore Versantis' commitment to improving patient outcomes for millions affected by liver conditions and related disorders.

Numbrs, headquartered in Zurich, Switzerland, is a customer-focused financial services company. It offers a mobile banking platform that allows users to manage their existing bank accounts and personal finances, and purchase financial products from various providers at competitive prices. Numbrs, with over 100 employees, does not operate as a bank itself.

Cunesoft GmbH is a provider of cloud-based regulatory compliance software solutions tailored for the life sciences industry. Founded in 2013 and headquartered in Munich, Germany, with additional offices in Princeton, New Jersey, and Bengaluru, India, Cunesoft offers a range of Software as a Service (SaaS) products. These include cune-IDMP for regulatory master data management, cune-eCTD for electronic submission management, and cune-Track for regulatory task management. Other solutions include cune-RDMS for document navigation and tagging, cune-SOP for standard operating procedures, and cune-Portal for document sharing. Cunesoft also provides outsourcing services for regulatory procedures and submission documentation. The company is recognized for its reliability, security, and commitment to continuous innovation, serving both small and medium enterprises as well as divisions of large pharmaceutical companies globally.

iMusician Digital AG is a Swiss-based online platform founded in 2007, dedicated to empowering musicians in managing, selling, and monetizing their music. Located in Zurich, the company offers a comprehensive suite of tools that enables artists to distribute their music across major streaming services and sales platforms. iMusician focuses on simplifying the process for musicians by providing real-time sales tracking and copyright management, allowing them to concentrate on their creative work. With a small, passionate international team, iMusician Digital strives to support artists in navigating the complexities of the music industry and maximizing their revenue potential.

InSphero specializes in the production and application of organotypic 3D cell culture models for various applications. It offers a range of assay-ready microtissues derived from liver, pancreas, tumor, heart, brain, and skin cells, along with optimized media and platforms for their generation and cultivation. The company's products include human and rat liver microtissues, pancreatic microislets, tumor microtissues, custom-made microtissues, cytotoxicity assay kits, and a human liver disease discovery platform. InSphero also provides services such as hepatotoxicity testing, oncology service packs, and embryonic stem cell test services. Its 3D InSight microtissues are used in toxicity testing, drug metabolism studies, cancer research, stem cell research, and disease modeling.

iMusician Digital AG is a Swiss-based online platform founded in 2007, dedicated to empowering musicians in managing, selling, and monetizing their music. Located in Zurich, the company offers a comprehensive suite of tools that enables artists to distribute their music across major streaming services and sales platforms. iMusician focuses on simplifying the process for musicians by providing real-time sales tracking and copyright management, allowing them to concentrate on their creative work. With a small, passionate international team, iMusician Digital strives to support artists in navigating the complexities of the music industry and maximizing their revenue potential.